There were 7 such patients (patient #1, 4, 9, 15, 17, 18 and 21) that fit in this category, indicating that about 26% (7 out of 27) of the GBM patients exhibit elevated WEE1/IDH2 signaling (90% CI: 0.128–0.432). This evidence concerns the gene IDH2 and glioblastoma.